IntrinsicIntrinsic

METTLER TOLEDO INTERNATIONAL INC/

MTD
🏢 Laboratory Analytical Instruments

Business Operations Summary

Mettler-Toledo International Inc. is a leading global supplier of precision instruments and services, holding global number-one market positions in most of its businesses. The company's solutions are critical in research and development, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Its products are sold in more than 140 countries with a direct presence in approximately 40 countries. The business is geographically diversified, with net sales in 2025 derived 42% from North and South America, 29% from Europe, and 29% from Asia and other countries.

The company holds strong leadership positions in all of its businesses and believes it holds global number-one market positions in most of them. Primary competitors are numerous regional or specialized competitors, many of which are well established in their markets, including divisions of larger companies with potentially greater financial and other resources. Competitive advantages include worldwide market leadership positions, global brand and reputation, a track record of technological innovation, a comprehensive high-quality solution offering, a global sales and service offering, a large installed base of instruments, and diversification of the revenue base by geographic region, product range, application, and customer. The company estimates it has the largest installed base of weighing instruments in the world.

The company generates revenue through the manufacture and sale of precision instruments and the provision of value-added services. Net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance, and spare parts. Service accounted for approximately 25% of net sales in 2025 , 24% in 2024 , and 23% in 2023 . The customer base is diversified by industry and by individual end-customer, with no single end-customer accounting for more than 1% of 2025 net sales . Products are sold through a variety of distribution channels, with sales through direct channels exceeding sales through indirect channels.

The company's principal products and services are organized into three categories: laboratory, industrial, and retail. The laboratory instruments and related service business accounted for approximately 56% of net sales in 2025 and 2024 , compared to 55% in 2023 . Laboratory instruments include balances, liquid pipetting solutions, automated lab reactors, titrators, pH meters, process analytics sensors, physical value analyzers, thermal analysis systems, UV/VIS spectrophotometers, moisture analyzers, cell counters, and the LabX software platform. The industrial instruments and related service business accounted for approximately 39% of net sales in 2025 , 2024 , and 2023 . Industrial products include industrial scales, terminals, transportation and logistics solutions, vehicle scale systems, industrial software, and product inspection systems such as metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. The retail business accounted for approximately 5% of net sales in 2025 and 2024 , compared to 6% in 2023 . Retail offerings include weighing and software solutions for supermarkets and food retail businesses, including automated packaging and labeling solutions.

In 2025, the company acquired several North American distributors that increased direct market access while expanding the service business, as well as an extension of its life science equipment offering and other acquisitions. The cumulative initial cash payments were $93.8 million and the company may be required to pay additional consideration of up to $35.5 million . Goodwill recorded in connection with the acquisitions totaled $56.0 million . The company also recorded $38.9 million of identified intangibles primarily pertaining to customer relationships, which will be amortized on a straight-line basis over 5 to 10 years . In November 2025, the Board of Directors authorized an additional $2.75 billion to the share repurchase program, which had $3.7 billion of remaining availability as of December 31, 2025. During 2025, the company spent $800 million on the repurchase of 646,608 shares at an average price per share of $1,237.18 . In January 2025, the company entered into an agreement to issue and sell EUR 100 million 10 1/2-year Senior Notes with a fixed interest rate of 3.80% in a private placement, which will mature in July 2035.

Net sales in U.S. dollars increased 4% in 2025 and 2% in 2024 . Excluding the effect of currency exchange rate fluctuations, net sales increased 3% in both 2025 and 2024 . Net sales were $4.0 billion for the year ended December 31, 2025, compared to $3.9 billion in 2024 and $3.8 billion in 2023. Gross profit as a percentage of net sales was 59.4% for 2025 , 60.1% for 2024 , and 59.2% for 2023 . Net earnings were $869.193 million in 2025, compared to $863.140 million in 2024 and $788.778 million in 2023. Diluted earnings per common share were $42.05 in 2025, compared to $40.48 in 2024 and $35.90 in 2023. Cash provided by operating activities totaled $955.8 million in 2025, compared to $968.3 million in 2024 and $965.9 million in 2023.

Business Outlook & Future Growth Drivers

The company expects to continue to benefit from market trends toward automation and digitalization in 2026. It also anticipates future opportunities with customer replacement cycles and investments in on/near-shoring activities. However, timing remains unclear and many end-markets, including pharma/biopharmaceutical, food, and chemical, remain challenged and continue to face uncertainty. The company believes it will benefit from favorable pharma/biopharma market trends in the future and from increased customer demand for automation, digitalization, and safety; new facility investments; and continued focus on regulatory compliance including data integrity requirements. In 2026, the company will continue to pursue overall business growth strategies including gaining market share, focusing on faster-growing markets, extending its technology lead, expanding margins, and pursuing strategic acquisitions.

The company's growth strategy includes gaining market share through its global sales and marketing initiative, Spinnaker, which uses digitalization and advanced data analytics to identify, prioritize, and pursue growth opportunities. Emerging markets, comprising Asia (excluding Japan), Eastern Europe, Latin America, the Middle East, and Africa, account for approximately 33% of total net sales , of which 16% relates to China . The company has a two-pronged strategy in emerging markets: to capitalize on long-term growth opportunities and to leverage low-cost manufacturing operations in China, which was recently designated a Lighthouse site by the World Economic Forum's Global Lighthouse Network. The company has a nearly 40-year track record in China, and sales in Asia have grown more than 10% on a compound annual growth basis in local currencies since 2000 . Overall, versus the prior year, the company experienced a 3% increase in emerging market local currency sales by destination during 2025 , which included a local currency sales increase of 1% in China and 5% in other emerging markets . The company also pursues other faster-growth vertical markets including semiconductors, advanced materials, and new energy.

The company continues to strive to improve its margins by enhancing its value proposition via innovation, more effectively pricing products and services, optimizing its cost structure, and improving its mix in higher-margin businesses such as service. The company has implemented productivity and cost savings initiatives over recent years to mitigate reduced volume, while also focusing on reallocating resources to better align its cost structure to support investments in market penetration initiatives, higher-growth/profitable areas, and opportunities for margin improvement. The company has also implemented global procurement and supply chain management programs over the last several years aimed at lowering costs and has increased its focus on these programs with its SternDrive initiative, a global operational excellence program for continuous improvement efforts within supply chain, manufacturing, and back-office operations. Blue Ocean is also an important enabler of various margin expansion initiatives.

Capital expenditures in 2026 are expected to approximate $130 million , subject to business and economic conditions and foreign currency fluctuations. The company continues to explore potential acquisitions. In 2026, the company intends to spend in the range of $825 million to $875 million on the repurchase of shares, subject to business and economic conditions. The company's share repurchase program does not obligate it to acquire any specific number of shares. The company expects to make interest payments of approximately $71.0 million during 2026 associated with its debt outstanding as of December 31, 2025.

The company faces a difficult environment due to global trade disputes/tariffs, governmental policies, and geopolitics that increased uncertainty in end markets and the global economy, while having a negative impact on customer behavior and import costs. The company estimates it incurred costs before mitigation actions from the 2025 incremental tariffs of approximately $50 million in 2025. Incremental tariff rates are currently 15% on imports from Switzerland , 25% on non-USMCA imports from Mexico , 30% on imports from China , 15% on imports from the European Union , and 10% on imports from the United Kingdom . The U.S. government has indicated it may make further changes to tariff rates in the future that may adversely impact financial results in future periods. The recent escalation in global trade disputes/tariffs has increased economic uncertainty in end markets and the global economic environment, including increasing the risk of recession in many countries, and market conditions may change quickly.

Many of the company's end-markets, including pharma/biopharmaceutical, food, and chemical, remain challenged and continue to face uncertainty. The company recently experienced reduced demand in these segments, which negatively impacted net sales over the past few years. Market demand in pharma/biopharmaceutical was particularly impacted in 2023 after significant growth during the COVID-19 pandemic. The company's laboratory sales grew modestly in 2025 including improved bioprocessing market conditions, while biotech research and academia market conditions were softer. China and emerging market economies have historically been an important source of growth, but China has historically been volatile, and market conditions may change unfavorably due to various factors. The company's core industrial-related products are especially sensitive to changes in economic growth.

Major Risk Factors & Challenges

The company faces significant risks from its international operations, particularly its concentration in China, which accounted for 16% of sales to external customers , 29% of total segment profit , and approximately 29% of global production during 2025. Market demand in China declined significantly during the second half of 2023, which continued in 2024 . The company is also subject to risks from tariffs and trade restrictions, estimating it incurred costs of approximately $50 million from 2025 incremental tariffs. Currency fluctuations pose a material risk, with a 1% strengthening of the Swiss franc against the euro estimated to reduce earnings before tax by approximately $2.8 million to $3.1 million annually , and a 1% weakening of the Chinese renminbi against the U.S. dollar estimated to reduce earnings before tax by approximately $2.2 million to $2.6 million annually . A prolonged downturn or additional consolidation in the pharma/biopharmaceutical, food manufacturing, and chemical industries could adversely affect operating results, as the company recently experienced reduced demand in these segments . The company's debt level of approximately $2.2 billion as of December 31, 2025, net of cash of $66.9 million , could make it more difficult to satisfy obligations and limit the ability to respond to business opportunities.

Management Priorities & Sentiments

Management's message emphasizes the company's resilience and agility in a difficult environment due to global trade disputes/tariffs, governmental policies, and geopolitics. Management highlights that the team's resilience and agility, and the company's pricing, supply chain, productivity, and cost savings initiatives, were critical to mitigating these challenges. The company continues to benefit from strong global leadership positions, a diversified customer base, innovative product offering, investment in emerging markets, a significant installed base, and the impact of sophisticated global sales and marketing programs. Management states that the company is well positioned and has continued to make investments to further strengthen its portfolio and capture future growth opportunities. As the company enters 2026, it expects to continue to benefit from market trends toward automation and digitalization and anticipates future opportunities with customer replacement cycles and investments in on/near-shoring activities. Management also notes that the company has implemented various actions to fully offset the effect of the current incremental tariffs in 2026 .

References

  1. [1] Item 1, Business — Sales and Service Market Organizations
  2. [2] Item 1, Business — Sales and Service Market Organizations
  3. [3] Item 1, Business — Sales and Service Market Organizations
  4. [4] Item 1, Business — Customers and Distribution
  5. [5] Item 1, Business — Laboratory Instruments
  6. [6] Item 1, Business — Laboratory Instruments
  7. [7] Item 1, Business — Laboratory Instruments
  8. [8] Item 1, Business — Industrial Instruments
  9. [9] Item 1, Business — Industrial Instruments
  10. [10] Item 1, Business — Industrial Instruments
  11. [11] Item 1, Business — Retail Weighing Solutions
  12. [12] Item 1, Business — Retail Weighing Solutions
  13. [13] Item 1, Business — Retail Weighing Solutions
  14. [14] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  15. [15] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  16. [16] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  17. [17] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  18. [18] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  19. [19] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities
  20. [20] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities
  21. [21] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities
  22. [22] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities
  23. [23] Item 5, Market for Registrant's Common Equity — Purchases of Equity Securities
  24. [24] Item 7, MD&A — Senior Notes and Credit Facility Agreement
  25. [25] Item 7, MD&A — Senior Notes and Credit Facility Agreement
  26. [26] Item 7, MD&A — Overview
  27. [27] Item 7, MD&A — Overview
  28. [28] Item 7, MD&A — Overview
  29. [29] Item 7, MD&A — Overview
  30. [30] Item 7, MD&A — Net sales
  31. [31] Item 7, MD&A — Net sales
  32. [32] Item 7, MD&A — Net sales
  33. [33] Item 7, MD&A — Gross profit
  34. [34] Item 7, MD&A — Gross profit
  35. [35] Item 7, MD&A — Gross profit
  36. [36] Item 8, Consolidated Statements of Operations
  37. [37] Item 8, Consolidated Statements of Operations
  38. [38] Item 8, Consolidated Statements of Operations
  39. [39] Item 8, Consolidated Statements of Operations
  40. [40] Item 8, Consolidated Statements of Operations
  41. [41] Item 8, Consolidated Statements of Operations
  42. [42] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  43. [43] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  44. [44] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  45. [45] Item 7, MD&A — Overview
  46. [46] Item 7, MD&A — Overview
  47. [47] Item 7, MD&A — Overview
  48. [48] Item 7, MD&A — Overview
  49. [49] Item 7, MD&A — Overview
  50. [50] Item 7, MD&A — Overview
  51. [51] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  52. [52] Item 7, MD&A — Liquidity, Capital Resources, and Future Cash Requirements
  53. [53] Item 7, MD&A — Senior Notes and Credit Facility Agreement
  54. [54] Item 7, MD&A — Results of Operations — Consolidated
  55. [55] Item 7, MD&A — Results of Operations — Consolidated
  56. [56] Item 7, MD&A — Results of Operations — Consolidated
  57. [57] Item 7, MD&A — Results of Operations — Consolidated
  58. [58] Item 7, MD&A — Results of Operations — Consolidated
  59. [59] Item 7, MD&A — Results of Operations — Consolidated
  60. [60] Item 1A, Risk Factors — Operational Risks
  61. [61] Item 1A, Risk Factors — Operational Risks
  62. [62] Item 1A, Risk Factors — Operational Risks
  63. [63] Item 1A, Risk Factors — Operational Risks
  64. [64] Item 7, MD&A — Results of Operations — Consolidated
  65. [65] Item 7A, Quantitative and Qualitative Disclosures about Market Risk
  66. [66] Item 7A, Quantitative and Qualitative Disclosures about Market Risk
  67. [67] Item 1A, Risk Factors — Strategic Risks
  68. [68] Item 1A, Risk Factors — Risks Related to Our Debt
  69. [69] Item 1A, Risk Factors — Risks Related to Our Debt
  70. [70] Item 7, MD&A — Results of Operations — Consolidated
  71. [71] Item 8, Consolidated Statements of Operations
  72. [72] Item 8, Consolidated Statements of Operations
  73. [73] Item 8, Consolidated Statements of Operations
  74. [74] Item 8, Consolidated Statements of Operations
  75. [75] Item 8, Consolidated Statements of Operations
  76. [76] Item 8, Consolidated Statements of Operations
  77. [77] Item 8, Consolidated Statements of Operations
  78. [78] Item 8, Consolidated Statements of Operations
  79. [79] Item 8, Consolidated Statements of Operations
  80. [80] Item 7, MD&A — Gross profit
  81. [81] Item 7, MD&A — Gross profit
  82. [82] Item 7, MD&A — Gross profit
  83. [83] Item 8, Consolidated Statements of Operations
  84. [84] Item 8, Consolidated Statements of Operations
  85. [85] Item 8, Consolidated Statements of Operations
  86. [86] Item 8, Consolidated Statements of Cash Flows
  87. [87] Item 8, Consolidated Statements of Cash Flows
  88. [88] Item 8, Consolidated Statements of Cash Flows
  89. [89] Item 7, MD&A — Senior Notes and Credit Facility Agreement
  90. [90] Item 8, Consolidated Balance Sheets
  91. [91] Item 7, MD&A — Interest expense and taxes
  92. [92] Item 7, MD&A — Interest expense and taxes
  93. [93] Item 7, MD&A — Interest expense and taxes
  94. [94] Item 7, MD&A — Interest expense and taxes
  95. [95] Item 7, MD&A — Interest expense and taxes
  96. [96] Item 7, MD&A — Restructuring charges
  97. [97] Item 7, MD&A — Restructuring charges
  98. [98] Item 7, MD&A — Restructuring charges
  99. [99] Item 7, MD&A — Results of Operations by Operating Segment — U.S. Operations
  100. [100] Item 7, MD&A — Results of Operations by Operating Segment — Swiss Operations
  101. [101] Item 7, MD&A — Results of Operations by Operating Segment — Western European Operations
  102. [102] Item 7, MD&A — Results of Operations by Operating Segment — Chinese Operations
  103. [103] Item 7, MD&A — Results of Operations by Operating Segment — Other Operations

Report on Jun 8, 2026